LDCA
CAS No. 349106-80-5
LDCA( —— )
Catalog No. M35413 CAS No. 349106-80-5
LDCA is a double-hit metabolic regulator that exhibits potent anti-proliferative activity. lDCA competitively inhibits LDH-A enzyme activity, alters mitochondrial hyperpolarization and simultaneously subverts apoptosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 39 | In Stock |
|
| 25MG | 79 | In Stock |
|
| 50MG | 128 | In Stock |
|
| 100MG | 207 | In Stock |
|
| 200MG | 295 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLDCA
-
NoteResearch use only, not for human use.
-
Brief DescriptionLDCA is a double-hit metabolic regulator that exhibits potent anti-proliferative activity. lDCA competitively inhibits LDH-A enzyme activity, alters mitochondrial hyperpolarization and simultaneously subverts apoptosis.
-
DescriptionLDCA is a dual-hit metabolic modulator and inhibits LDH-A enzyme activity to stimulate apoptosis in the malignant population. LDCA can be used for the research of oncogenic progression.
-
In VitroLDCA (2-100 μM; 16-72 h) is used in combination with doxorubicin synergistically, enhances the growth inhibition and induces mitochondria-mediated apoptosis by recruiting the caspase cascade, restricting migration, and obviating the clonogenic outgrowth potential of melanoma cells.Cell Viability Assay Cell Line:B16-F10 cells Concentration:2-100 μM Incubation Time:72 h Result:Arrested cell growth with a dose-dependent cytotoxic effect and had a strong synergism with LDCA.Apoptosis Analysis Cell Line:B16-F10 cells Concentration:20 μM Incubation Time:24 h Result:Resulted 15% death when cells exposed to LDCA and caused 40% melanoma cell death combination synergistically with doxorubicin.Immunofluorescence Cell Line:B16-F10 cells Concentration:20 μM Incubation Time:16 h Result:Demonstrated thatcombination with doxorubicin resultantly affected cellular morphologywith condensed and fragmented nuclei.Cell Migration Assay Cell Line:B16-F10 cells Concentration:20 μM Incubation Time:16 h Result:Signicantly limited the migratory potential in the B16-F10 cells.
-
In VivoLDCA (2 mg/kg, iv., the 6th day, once) is used in combination with doxorubicin thwarts tumor growth kinetics to restrain oncogenic progression, thus accentuating survival in the model of murine melanoma.Animal Model:melanoma tumor model Dosage:2 mg/kg Administration:2 mg/kg, iv., the 6th day, once Result:Significantly increased mice survivability combination with doxorubicin, and relieved mice tumor necrosis phenomena.
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis | Dehydrogenase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number349106-80-5
-
Formula Weight256.49
-
Molecular FormulaC8H5Cl3FNO
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (389.88 mM; Ultrasonic (<60°C)
-
SMILESN(C(C(Cl)Cl)=O)C1=CC(Cl)=C(F)C=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Saha, Suchandrima, et al. The dual-hit metabolic modulator LDCA synergistically potentiates doxorubicin to selectively combat cancer-associated hallmarks. RSC Advances, 7(84), 53322–53333. doi:10.1039/c7ra08625c.
molnova catalog
related products
-
NSC49652
NSC49652 triggers apoptotic cell death dependent on p75NTR and JNK activity in neurons and melanoma cells, and inhibits tumor growth in a melanoma mouse model.
-
RSH-7
RSH-7 is a potent dual inhibitor of BTK and FLT3, with IC50s of 47 and 12 nM, respectively.RSH-7 has antiproliferative and antitumor activities, inducing apoptosis and inhibiting BTK and FLT3 signaling.
-
Exisulind
Exisulind induces apoptosis through the activation of protein kinase G (PKG). Exisulind exhibits antineoplastic activity in solid tumour and haematological cancer cell lines and is an inhibitor of tumour growth in rodent models of colon, prostate, bladder, mammary and lung cancer.
Cart
sales@molnova.com